Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356590 | 0.87 | AKT1 (0.42) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL658497 | 0.87 | CDK4 (0.36) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL659399 | 0.85 | CCNE1 (0.33) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL657216 | 0.84 | CDK2 (0.37) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL658869 | 0.84 | HDAC1 (0.36) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL658780 | 0.82 | HPGDS (0.40) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL657967 | 0.82 | AKT1 (0.42) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL3357617 | 0.82 | CCNE1 (0.40) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL657703 | 0.81 | HDAC1 (0.39) | CCNE1CDK2CDK4HDAC6HDAC1 | |
| SCHEMBL658275 | 0.81 | AKT1 (0.36) | CCNE1CDK2CDK4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CCNE1 1992/4885CDK2 213/4885CDK4 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.